With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Over the past several years, advances in research, treatment, and market dynamics have
impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They …

Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …

Ponatinib, the only approved all known-BCR:: ABL1 inhibitor, is a third-generation tyrosine-
kinase inhibitor (TKI) designed to inhibit BCR:: ABL1 with or without any single resistance …

Second-generation tyrosine kinase inhibitors (2GTKI) are more effective in inducing rapid
molecular responses than imatinib when used first-line in patients with chronic myeloid …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR:: ABL1
tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have been established as standard …

Abstract Purpose of Review Chronic myeloid leukemia (CML) is a disease that previously
signified a poor prognosis, but treatment options and outcomes have improved over the last …

Background Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with
robust activity in Philadelphia chromosome–positive leukemias. Herein, we report the long …

The introduction in 1998 of imatinib mesylate (IM), a first-generation BCR-ABL1 tyrosine
kinase inhibitor (1G-TKI), to the treatment of chronic myelogenous leukemia patients in the …

Introduction Ponatinib exhibits a high inhibition potency on wild-type and most mutated
forms of the BCR: ABL1 kinase, but also a significant cardiovascular toxicity. Improving the …